HAEMONETICS CORP HAE revenue by segment, product and geography
In its fiscal year ending 2026-03-31, HAEMONETICS CORP reported revenue across 3 business segments; the largest, Hospital, was $588M, 44.1% of the filed sum (+4.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Hospital$588M44.1%+4.3% yoy
- Plasma$524M39.3%-2.0% yoy
- Blood Center$221M16.6%-15.3% yoy
Members sum to the consolidated $1.33B for this period.
- Hospital Productsand Services$588M72.7%+4.3% yoy
- Blood Center Productsand Services$221M27.3%-15.3% yoy
Members sum to $810M against $1.33B consolidated (residual $524M) - eliminations or corporate lines the filer did not tag on this axis.
- United States$982M73.6%-2.8% yoy
- Europe$185M13.9%+5.3% yoy
- Asia$87.2M6.5%-5.5% yoy
- Japan$68.2M5.1%+9.3% yoy
- Other Countryor Region$11.4M0.9%-41.5% yoy
Members sum to the consolidated $1.33B for this period.
- Hospital$144M42.3%no prior
- Plasma$139M41.0%no prior
- Blood Center$56.6M16.7%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.